Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy

NCT04383119 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT04383119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04383119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy
Lead sponsor
Italian Sarcoma Group
Phase
Phase 2
Overall status
Recruiting
Start date
October 29, 2021
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma of ovary, soft tissue sarcoma